

**Brian Beck, M.D., Ph.D.**  
Cognitive Clinical Trials Research  
8901 E. Pima Center Parkway, Suite 115  
Scottsdale, AZ 85258

**CONTACT INFORMATION:**

Site Selection and Information:  
Bobbie Theodore, Alliance Director  
Tel. (916) 939-6696  
Fax (208) 575-3169  
Email: clinicaltrials@alliancesites.com

**AFFILIATIONS:**

Mariposa Point of Gilbert/CCT  
1445 Willis Road  
Gilbert, AZ 85297

Mariposa Point of Mesa/CCT  
1248 South Crismon Road  
Mesa, AZ 85209

Generations at Agritopia/CCT  
2811 E. Agritopia Loop S  
Gilbert, AZ 85296

Generations at Ahwatukee/CCT  
16025 S. 50th Street  
Phoenix, AZ 85048

**EDUCATION:**

2001 – 2010 M.D.  
Indiana University School of Medicine, Indianapolis, IN

2003 – 2008 Ph.D., Biochemistry & Molecular Biology  
Indiana University School of Medicine, Indianapolis, IN

1994 – 1998 B.S., Chemistry & Biology  
Butler University, Indianapolis, IN

**INTERSHIPS AND RESIDENCIES:**

2013 – 2014 Adult Neurology Chief Resident  
Barrow Neurological Institute, Phoenix, AZ

**INTERNSHIPS AND RESIDENCIES (*continued*):**

2011 – 2014 Adult Neurology Resident  
Barrow Neurological Institute, Phoenix, AZ

2010 – 2011 Preliminary Medicine Resident  
Medical Center of Central Georgia, Macon, GA

**LICENSURE:**

2014-present Arizona Medical License (49520)

2014-present DEA License

**CERTIFICATION:**

2014 – Present Board-Certified Neurology, State of Arizona

**PROFESSIONAL EXPERIENCE:**

*Principal Investigator*, 2018 – present  
Cognitive Clinical Trials Research, Scottsdale, AZ

*Neurologist*, 2014 – present  
Gilbert Neurology, Gilbert, AZ

**INVESTIGATOR EXPERIENCE:**

Alzheimer's Disease • Dementia • Stroke

**INVESTIGATOR EXPERIENCE:**

*Alzheimer's Disease*

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-design Study to Assess the Efficacy, Safety and Tolerability of XXX for the Treatment of Agitation in Patients with Dementia of the Alzheimer's Type

A Phase III, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of XXX for the Treatment of Agitation in Subjects With Dementia of the Alzheimer's Type

A Phase II, Randomized, Double-blind, Placebo-controlled, 3-Arm Parallel Design Study to Evaluate the Effects of XXX in Patients with Early Stage Alzheimer's Disease

**INVESTIGATOR EXPERIENCE** (*continued*):

A 12-Month, Open-Label Safety Study of XXX in Mild-to-moderate Alzheimer's Disease Patients

A Phase IIb, Randomized, Double-blind, Placebo-controlled, Multiple Dose, Biomarker and Safety Study of XXX in Mild-to-moderate Alzheimer's Disease Patients

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of Pulsed XXX Infusions in Subjects with Severe Alzheimer's Disease

A Phase III Safety and Efficacy Study of XXX in Subjects with Evidence of Early Alzheimer's Disease

PAS2-OSB Lead New Enrollment Study

***Dementia***

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study with an Open-Label Extension to Assess the Efficacy and Safety of XXX in the Treatment of Agitation in Patients with Dementia, Including Alzheimer's Disease

Imaging Dementia – Evidence for Amyloid Scanning (IDEAS)

***Stroke***

WAVECrest Vs. Watchman Transseptal LAA Closure to Reduce AF-Mediated Stroke 2 (WAVECREST2)

A Phase I/II, Multi-Center, Open-Label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic Mesenchymal Bone Marrow Cells to Subjects with Severe Ischemic Stroke

**PUBLICATIONS:**

Beck BD, Chang GY. Post-Ictal, Lateralized, Hyperkinetic Motor Behavior. *Epilepsy Behav Case Rep.* 2013. 1: 20-21.

Hromas R, Williamson EA, Fnu S, Lee YJ, Park SJ, Beck BD, You JS, Laitao A, Nickoloff JA, Lee SH. Chk1 Phosphorylation of Metnase Enhances DNA Repair But Inhibits Replication Fork Restart. *Oncogene.* 2012. 31(38): 4245-54.

Park SJ, Beck BD, Saadatzadeh MR, Haneline LS, Clapp DW, Lee SH. Fanconi Anemia D2 Protein is an Apoptotic Target Mediated by Caspases. *J Cell Biochem.* 2011. 112(9): 2383-91.

**PUBLICATIONS** (*continued*):

Beck BD, Lee SS, Williamson E, Hromas RA, Lee SH. Biochemical Characterization of Metnase's Endonuclease Activity and Its Role in NHEJ Repair. *Biochemistry*. 2011. 50(20): 4360-70.

Beck BD, Lee SS, Hromas R, Lee SH. Regulation of Metnase's TIR Binding Activity by its Binding Partner, Pso4. *Arch Biochem Biophys*. 2010. 498(2): 89-94.

Wray J, Williamson EA, Royce M, Shaheen M, Beck BD, Lee SH, Nickoloff JA, Hromas R. Metnase Mediates Resistance to Topoisomerase II Inhibitors in Breast Cancer Cells. *PLoS One*. 2009. 4(4): e5323.

Beck BD, Hah DS, Lee SH. XPB and XPD Between Transcription and DNA Repair. *Adv Exp Med Biol*. 2008. 637: 39-46.

Williamson EA, Rasila KK, Corwin LK, Wray J, Beck BD, Severns V, Mobarak C, Lee SH, Nickoloff JA, Hromas R. The SET and Transposase Domain Metnase Enhances Chromosome Decatenation: Regulation by Automethylation. *Nucleic Acids Res*. 2008. 36(18): 5822-31.

Beck BD, Park SJ, Lee YJ, Roman Y, Hromas RA, Lee SH. Human Pso4 is a Metnase (SETMAR)-Binding Partner That Regulates Metnase Function in DNA Repair. *J Biol Chem*. 2008. 283(14): 9023-30.

Park SJ, Lee YJ, Beck BD, Lee SH. A Positive Involvement of RecQL4 in UV-Induced S-Phase Arrest. *DNA Cell Biol*. 2006. 25(12): 696-703.

Park SJ, Ciccone SL, Beck BD, Hwang B, Freie B, Clapp DW, Lee SH. Oxidative Stress/Damage Induces Multimerization and Interaction of Fanconi Anemia Proteins. *J Biol Chem*. 2004. 279(29): 30053-9.

Dynlacht JR, Bittner ME, Bethel JA, Beck BD. The Non-Homologous End-Joining Pathway Is Not Involved in the Radiosensitization of Mammalian Cells By Heat Shock. *J Cell Physiol*. 2003. 196(3): 557-64.

Zhu WG, Seno JD, Beck BD, Dynlacht JR. Translocation of MRE11 From the Nucleus to the Cytoplasm as a Mechanism of Radiosensitization By Heat. *Radiat Res*. 2001. 156(1): 95-102.

Beck BD, Dynlacht JR. Heat-Induced Aggregation of XRCC5 (Ku80) in Nontolerant and Thermotolerant Cells. *Radiat Res*. 2001. 156(6): 767-74.